Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions
Ublituximab was generally well tolerated, with no unexpected safety signals
BLA submission targeted in Q3 2021
https://finance.yahoo.com/news/tg-therapeutics-announces-positive-results-113000006.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.